Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.43 USD

140.43
1,106,202

-2.57 (-1.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $140.34 -0.09 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise

by Zacks Equity Research

Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans

by Zacks Equity Research

SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.

Zacks Equity Research

Breast Health Performance Likely to Aid Hologic's Q1 Earnings

by Zacks Equity Research

In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.

Zacks Equity Research

Revvity Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

Zacks Equity Research

Can Masimo (MASI) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Cardinal Health to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.

Zacks Equity Research

Premier Protein Momentum Likely to Fuel BellRing Brands' Q1 Earnings

by Zacks Equity Research

BRBR is expected to have gained from strong volume growth for Premier Protein in the first quarter of fiscal 2025.

Zacks Equity Research

BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech

by Zacks Equity Research

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Zacks Equity Research

ISRG Stock Falls Despite Q4 Earnings Beat & Robust Procedures

by Zacks Equity Research

ISRG's fourth-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Zacks Equity Research

TEM Stock Rises on Launch of AI-Powered Health Concierge App

by Zacks Equity Research

Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.

Zacks Equity Research

Here's Why you Should Add Nevro Stock to Your Portfolio Now

by Zacks Equity Research

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.

Zacks Equity Research

Reasons to Hold Avanos Medical Stock in Your Portfolio Now

by Zacks Equity Research

AVNS' strong product line and focus on R&D raise optimism about the stock.

Zacks Equity Research

Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.

Zacks Equity Research

Here's Why You Should Add Surmodics Stock to Your Portfolio Now

by Zacks Equity Research

SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.

Zacks Equity Research

Here's Why Masimo (MASI) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

Zacks Equity Research

GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub

by Zacks Equity Research

GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.

Zacks Equity Research

Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?

by Zacks Equity Research

TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Masimo Stock Gains Following Solid Preliminary Q4 Revenues

by Zacks Equity Research

MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.

Zacks Equity Research

TMDX Stock Down Despite Responding to Misleading Short-Seller Report

by Zacks Equity Research

TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.

Zacks Equity Research

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

by Zacks Equity Research

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks Equity Research

Reasons to Add GE HealthCare Stock to Your Portfolio Now

by Zacks Equity Research

GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.

Zacks Equity Research

GEHC Stock Gains on Long-Term Collaboration With Sutter Health

by Zacks Equity Research

GE HealthCare announces a seven-year strategic collaboration with Sutter Health.

Zacks Equity Research

Cardinal Health Stock May Gain With New Texas Distribution Center

by Zacks Equity Research

CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.